Life Science IPOs: Discounts, Then Downgrades
You may also be interested in...
Can biotech breakthrough the IPO malaise in 2011 with new formulations?
India’s National Cancer Grid pilots pooled procurement for 40 drugs including trastuzumab, imatinib, and pemetrexed, delivering median savings of over 80%. Experts discuss with Scrip the prospects of scaling the initiative and what it may mean for pharma’s margins and go-to-market strategy.